GlassScriptPhysician profile
Abdalla Sholi
NPI 1275523052
$575,546.87
in general payments reported to CMS, 2019-2025
53 companies · $132K in 2025
The $132K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $21K · 2021: $39K · 2022: $82K · 2023: $114K · 2024: $137K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $299K · Travel and Lodging: $40K · Food and Beverage: $16K · Consulting Fee: $16K · Honoraria: $5,855 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,600 · Education: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $298,961.50 |
| Travel and Lodging | $40,045.70 |
| Food and Beverage | $16,358.70 |
| Consulting Fee | $15,805.00 |
| Honoraria | $5,855.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,600.00 |
| Education | $499.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $162,178.42 | 2019-2025 | Jakafi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $148,673.58 | 2019-2025 | Calquence, Imfinzi, Tagrisso |
| Glaxosmithkline, LLC. | $116,207.83 | 2020-2025 | Ojjaara, Jemperli, Shingrix |
| Daiichi Sankyo INC. | $45,321.26 | 2022-2025 | Datroway, Enhertu |
| Jazz Pharmaceuticals INC. | $30,423.01 | 2019-2025 | |
| Sobi, INC | $26,945.48 | 2024-2025 | |
| Cti Biopharma Corp. | $9,335.82 | 2022-2023 | Vonjo |
| Novocure INC. | $5,664.49 | 2023-2025 | Optune Lua (Novottf-200t), Optune Lua (Novottf-200t), Optune |
| Gilead Sciences, INC. | $5,590.17 | 2023-2025 | Trodelvy |
| Janssen Biotech, INC. | $3,895.45 | 2019-2025 | Erleada, Rybrevant, Tecvayli |
| Pfizer INC. | $3,201.38 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $3,071.80 | 2022-2025 | Erleada, Tecvayli, Talvey |
| Abbvie INC. | $1,786.50 | 2023-2025 | Imbruvica |
| Exelixis INC. | $1,690.90 | 2019-2023 | Cabometyx |
| E.R. Squibb & Sons, L.L.C. | $1,346.29 | 2019-2025 | Reblozyl, Opdivo, Eliquis |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $1,305.00 | 2025 | Besremi |
| Novartis Pharmaceuticals Corporation | $890.26 | 2019-2025 | |
| Genzyme Corporation | $747.36 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $609.01 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $537.79 | 2019-2024 | Soliris |
| Amgen INC. | $529.89 | 2019-2025 | Vectibix, Lumakras, Imdelltra (Amg 757) |
| Genentech USA, INC. | $492.62 | 2019-2023 | Lunsumio, Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $482.28 | 2019-2025 | |
| Stemline Therapeutics INC. | $471.81 | 2019-2025 | Orserdu, Elzonris |
| Beigene USA, INC. | $450.37 | 2021-2024 | Brukinsa |
| Seagen INC. | $332.58 | 2019-2024 | |
| Lilly USA, LLC | $266.87 | 2022-2024 | Verzenio, Jaypirca |
| Caris Mpi, INC. | $263.84 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $251.00 | 2023-2024 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $249.09 | 2023-2024 | Iclusig, Fruzaqla |
| Pharmacosmos Therapeutics INC. | $220.69 | 2023-2025 | Cosela, Monoferric |
| Merck Sharp & Dohme LLC | $187.01 | 2019-2024 | Keytruda |
| Menarini Silicon Biosystems, INC. | $162.61 | 2025 | |
| Eisai INC. | $162.27 | 2019-2025 | |
| Kyowa Kirin, INC. | $130.51 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $126.52 | 2019 | |
| Adc Therapeutics America, INC. | $125.00 | 2025 | |
| Astellas Pharma US INC | $124.74 | 2024 | Xtandi |
| Janssen Pharmaceuticals, INC | $124.74 | 2024 | Xarelto |
| Teleflex LLC | $118.12 | 2021-2022 | |
| Celgene Corporation | $111.93 | 2021 | |
| Genmab U.S., INC. | $110.42 | 2024 | Epkinly |
| Rigel Pharmaceuticals, INC. | $104.00 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Ipsen Biopharmaceuticals, INC | $100.62 | 2021 | |
| Dova Pharmaceuticals | $92.83 | 2021 | |
| Myriad Genetic Laboratories, INC. | $63.88 | 2024 | Myrisk |
| Tempus Ai, INC | $62.69 | 2024 | |
| Sumitomo Pharma America, INC. | $62.61 | 2023 | Orgovyx |
| Array Biopharma INC | $41.41 | 2025 | Braftovi, Mektovi, Lorbrena |
| Ge Healthcare | $34.19 | 2023 | |
| Taiho Oncology, INC. | $31.16 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $26.25 | 2019 | |
| Clovis Oncology, INC. | $10.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdalla Sholi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.